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Understanding the Techniques Used in Cost Effectiveness Studies
This review by Cohen and Reynolds provides an introduction to cost-effectivenessanalyses in order to help readers understand and interpret these studies. Cost
minimization studies try to establish the least costly intervention among clinically
equivalent strategies. Cost-effectiveness studies calculate incremental monetary costs,
comparedwith clinical benefits, which are expressed in nonmonetary terms, such as life
years gained or adverse events avoided. These types of studies are hampered by a lack of
consensus on what dollar threshold per outcome should be considered effective and
other factors, such as cost shifting, otherwise known as payer perspective, and extrap-
olated time horizons, which may extend beyond the length of the underlying clinical
trial data. See page 2119.
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Clinical Trials
Bosentan for Inoperable CTEPH
There is currently no approved medical therapy for inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH). Jaïs and
colleagues hypothesized that bosentan, which is effective for idiopathic pulmonary
artery hypertension (PAH), as well as PAH associated with other conditions,
would be effective. Over 150 patients were randomized to bosentan or placebo
for 16 weeks. Bosentan significantly reduced pulmonary vascular resistance
(PVR) and improved the cardiac index, but failed to improve 6-minute walk
distance. Further trials are needed to ascertain whether the improved PVR will
result in long term clinical benefits, but the treatment was well-tolerated and
appears promising. See page 2127. See figure.
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Clinical Trials
Multivendor Trial of CTCA Shows Good Diagnostic Accuracy
Meijboom and colleagues performed computed tomographic coronary angiogra-phy (CTCA) on patients referred for standard catheterization using machines
from 3 different vendors and at 3 different medical centers. No patients who met the
study criteria were excluded for poor image quality; likewise, no coronary artery
segments were excluded. In a patient-based analysis, the sensitivity for significantCAD
was 99%, positive predictive valuewas 86%, andnegative predictive valuewas 97%. In
a segment-based analysis, the positive predictive value was lower at 47% because of
“over-reading” of lesions 50% diameter stenosis, many of which were calcified.
64-slice CTCA can reliably rule out significant coronary artery disease, but may
overestimate the severity of some obstructions. See pages 2135 and 2145.
See figure.
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Cardiovascular Risk
LV Mass Strongly Linked to HF
This study evaluated the relationship of left ventricular (LV) mass and geometrymeasuredwith cardiacmagnetic resonance imaging (MRI) to incident cardiovas-
cular events. An increased LV mass to volume ratio was associated with stroke and
coronary heart disease, which included angina, heart failure (HF), and myocardial
infarction. Subjects with an LVmass95th percentile were 8 times more likely to be
diagnosed with HF compared with those with an LV mass 50th percentile. This
study confirms the link between increased LVmass and cardiovascular outcomes, and
provides guidance on the most appropriate MRI-based measurements. See page
2148. See figure.
Cardiovascular Risk
Link Between Stress and CVD Is Behavior
Although the association between psychological distress and cardiovascular risk isknown, the mechanisms are not. Hamer and colleagues studied this link in over
6,000 people. Psychological stress was measured with the 12-item version of the
General Health Questionnaire. Subjects were also questioned about behavioral issues
(smoking, alcohol intake, physical activity) and were assessed for other cardiac risk
factors. Over 7 years of follow-up, the risk of cardiovascular disease (CVD) increased
with increased psychological distress. Behavioral factors explained the largest propor-
tionof variance (65%).These data suggest that the behavioral factors of smoking and
physical inactivity are a significant link between psychological distress and increased
cardiac risk. See pages 2156 and 2163.
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Biomarkers in Heart Failure
ST2 Correlates With LVEDP; Produced by Endothelium Not Myocardium
SerumST2 is a recently identifiedbiomarker for patientswithmyocardial infarctionand/or congestive heart failure. Bartunek and colleagues measured serum ST2
levels in patients with pressure overload hypertrophy secondary to aortic stenosis (AS)
and congestive cardiomyopathy (CCM).TheST2was elevated inpatientswithAS and
CCM and correlated with B-type natriuretic peptide, C-reactive protein, and left
ventricular end-diastolic pressure (LVEDP). There was no difference in ST2 levels
between the coronary sinus and the aorta, suggesting that ST2 is not made in the
myocardium. Further studies confirmed that ST2 is produced in endothelial cells, not
myocardial cells. SerumST2 correlateswith diastolic load, but the source of serumST2
is extra-myocardial. See page 2166. See figure.(continued on page A-29)
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Cardiomyopathy
Characteristics of LDAC
Sen-Chowdhry and colleagues describe a cohort of patients whom they hypothe-sized had a left dominant subtype of arrhythmogenic right ventricular cardiomy-
opathy (ARVC) that they term left dominant arrhythmogenic cardiomyopathy
(LDAC). Subjects were recruited who had unexplained (infero)lateral T-wave inver-
sion, arrhythmia of left ventricular (LV) origin, and/or a relative with LDAC. Present-
ing symptoms were arrhythmia or chest pain, but not heart failure. Desmosomal
mutations, which are thought to cause ARVC, were found in one-third of the families
and one-half of the subjects. Cardiac magnetic resonance imaging showed LV late-
enhancement in a subepicardial/midwall distribution. LDACappears to be a variant of
ARVC; the authors suggest that the terminology be changed to “arrythmogenic
cardiomyopathy with subtypes of right, left, and biventricular.” See pages 2175
and 2188.
